Spanish Series of Patients Treated With the Radionuclide Lutetium177

ConditionsNeuroendocrine Tumors Intestinal Neoplasms Pancreatic Neoplasms Stomach Neoplasms Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Gastrointestinal Disease Intestinal Diseases Pancreatic Disease Endocrine System Diseases

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-100

SponsorSociedad Española de Medicina Nuclear e Imagen Molecular

About this trial

This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.

Eligibility criteria

Qualifiers

Written informed consent must be obtained prior to any data collection.

Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour

Aged ≥18 years.

Disqualifiers

None

Trial design

Treatments tested in this trial

Lutetium [177Lu] oxodotreotide/dotatate
Lutetium [177Lu] oxodotreotide/dotatate

Treatment groups

5,000 Participants

are divided into 1 treatment group

Locations20

Select a site below to view it on the map.

Sponsors and collaborators

Sociedad Española de Medicina Nuclear e Imagen Molecular

Lead sponsor

Source ClinicalTrials.gov